- Statement /
- Featured News /
European Medicines Agency (EMA) recently approved two European Novartis sites for commercial CAR-T manufacturing.
- Featured News /
Novartis reinforces commitment to patient access, pricing a EUR 1.85 billion sustainability-linked bond, a first in the healthcare industry.
- Featured News /
Driven by our passion for patients and grounded in our industry-leading pipeline of 45+ different compounds across 70+ development programs, Novartis is rapidly advancing novel cancer treatment approaches in areas of great medical need.
- Featured News /
Together in spirit. Find out how our associates all over the world are joining together to make a difference as we celebrate Pride 2020.
- Featured News /
Standing by people with sickle cell disease and their families
- Featured News /
Novartis is supporting World Cancer Day by reimagining cancer in the workplace through a dedicated global program.
- Featured News /
From January 21-24 2020, Novartis attended the World Economic Forum Annual Meeting in Davos, Switzerland.
- Featured News /
Novartis announced the company’s financial results for the second quarter and first half of 2022.
- Featured News /
The first pan-African Novartis Social Business stakeholder dialogue took place in Kampala, Uganda, on March 20, 2019.
Pagination
- ‹ Previous page
- 1
- …
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- …
- 20
- › Next page